Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease

Apomorphine and Levodopa Infusion Therapies for Advanced Parkinson’s Disease

Continuous infusion of levodopa or apomorphine provide constant dopaminergic stimulations are good alternatives to deep brain stimulation to control motor fluctuations in patients with advanced Parkinson’s disease (PD). Apomorphine provides motor benefit similar to dopamine, but its long-term use is...

Full description

Bibliographic Details
Main Author:	Angelo Antonini
Format:	Article
Language:	English
Published:	Korean Movement Disorder Society 2009-05-01
Series:	Journal of Movement Disorders
Subjects:	Parkinson’s disease Infusion Apomorphine Levodopa Carbidopa Duodopa DBS
Online Access:	http://e-jmd.org/upload/jmd-2-1-4-2.pdf

Similar Items

Gender disparity in access to advanced therapies for patients with Parkinson’s disease: a retrospective real-word study
by: Giuseppe Maccarrone, et al.
Published: (2024-09-01)

Long-term results of carbidopa/levodopa enteral suspension across the day in advanced Parkinson’s disease: Post-hoc analyses from a large 54-week trial
by: Rajesh Pahwa, et al.
Published: (2023-01-01)

Satisfaction and Preferences for Infusion Therapies in Advanced Parkinson’s Disease—Patient Perspective
by: Julia Węgrzynek-Gallina, et al.
Published: (2024-12-01)

Subcutaneous apomorphine in advanced Parkinson’s disease and its use in Indian population
by: Vinod Metta, et al.
Published: (2020-01-01)

Continuous intestinal infusion of levodopa–carbidopa in patients with advanced Parkinson's disease in Spain: Subanalysis by autonomous community
by: D. Santos-García, et al.
Published: (2021-03-01)

Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease
by: Ewa Papuć, et al.
Published: (2019-03-01)

The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson’s Disease: A Mini-Review
by: Germaine Hiu-Fai Chan
Published: (2022-06-01)

Intrajejunal Infusion of Levodopa-Carbidopa Gel Can Continuously Reduce the Severity of Dropped Head in Parkinson’s Disease
by: Hiroshi Kataoka, et al.
Published: (2017-10-01)

An updated calculator for determining levodopa-equivalent dose
by: D. Nyholm, et al.
Published: (2021-10-01)

Uso de la infusión intestinal continua de levodopa-carbidopa en pacientes con enfermedad de Parkinson avanzada en España. Subanálisis por comunidades autónomas
by: D. Santos-García, et al.
Published: (2021-03-01)

Levodopa-carbidopa intestinal gel therapy may cause “Supra-ON freezing of gate” in patients with Parkinson's disease with diphasic dyskinesia
by: Saki Oshiro, et al.
Published: (2021-12-01)

Continuous subcutaneous foslevodopa/foscarbidopa infusion for the treatment of motor fluctuations in Parkinson’s disease: Considerations for initiation and maintenance
by: Victor S.C. Fung, et al.
Published: (2024-01-01)

Apomorphine in the Treatment of Parkinson’s Disease
by: Serhat Özkan
Published: (2021-12-01)

Comparison Between Levodopa-Carbidopa Intestinal Gel Infusion and Subthalamic Nucleus Deep-Brain Stimulation for Advanced Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Xiao Dong Liu, et al.
Published: (2019-08-01)

The role and structure of the multidisciplinary team in the management of advanced Parkinson’s disease with a focus on the use of levodopa–carbidopa intestinal gel
by: Pedersen SW, et al.
Published: (2017-01-01)

Concomitant use of magnesium oxide significantly decreases absorption of levodopa preparations in patients with Parkinson’s disease
by: Noriyuki Miyaue, et al.
Published: (2023-01-01)

Levodopa-induced motor complications associated with benserazide and carbidopa in Parkinson’s disease: a disproportionality analysis of the FAERS database
by: Huaide Qiu, et al.
Published: (2025-03-01)

Levodopa-carbidopa intestinal gel therapy in Parkinson’s disease: Procedure complications
by: Luminita Celia Popa, et al.
Published: (2020-06-01)

Impact of Supporting People with Advanced Parkinson’s Disease on Carer’s Quality of Life and Burden
by: Modugno N, et al.
Published: (2020-12-01)

Complications of percutaneous endoscopic gastrostomy-jejunostomy for levodopa/carbidopa infusion in advanced Parkinson's disease
by: Ana Olivares, et al.
Published: (2012-03-01)

The human experience with intravenous levodopa
by: Shan H Siddiqi, et al.
Published: (2016-01-01)

Efficacy, safety and patient’s quality of life of long-term treatment with levodopa-carbidopa intestinal gel in advanced Parkinson’s disease in Romania: Results from GLORIA observational study
by: Jozsef Szasz, et al.
Published: (2020-03-01)

Continuous subcutaneous apomorphine infusion in the early phase of advanced Parkinson’s disease: A prospective study of 22 patients
by: Gustavo Fernández-Pajarín, et al.
Published: (2022-01-01)

Operation of the percutaneous endoscopic gastrostomy-jejunostomy tube without endoscopy in patients with Parkinson’s disease on levodopa-carbidopa intestinal gel infusion therapy
by: Yohei Mukai, et al.
Published: (2020-01-01)

Development of new levodopa treatment strategies in Parkinson’s disease—from bedside to bench to bedside
by: Sten-Magnus Aquilonius, et al.
Published: (2017-04-01)

Levodopa‐Carbidopa Intestinal Gel Injection for Patient with Severe Parkinson's Disease Followed by Total Hip Arthroplasty: A Case Report and Literature Review
by: Atsushi Imamura, et al.
Published: (2023-11-01)

Levodopa/carbidopa/entacapone versus levodopa/dopa-decarboxyiase inhibitor for the treatment of Parkinson's disease: systematic review, meta-analysis, and economic evaluation
by: Yi ZM, et al.
Published: (2018-04-01)

The pharmacokinetics of continuous subcutaneous levodopa/carbidopa infusion: Findings from the ND0612 clinical development program
by: Peter A. LeWitt, et al.
Published: (2022-11-01)

Apomorphine in the treatment of Parkinson's disease: a review
by: Renata Ramina Pessoa, et al.

Long-term effects of intrajejunal levodopa infusion on sleep in people with advanced Parkinson's disease
by: Ştefania Diaconu, et al.
Published: (2023-04-01)

Von Economo’s disease and postencephalitic parkinsonism responsive to carbidopa and levodopa
by: Bigman DY, et al.
Published: (2018-04-01)

Switching and Combining Device-Aided Therapies in Advanced Parkinson’s Disease: A Double Centre Retrospective Study
by: Dejan Georgiev, et al.
Published: (2022-03-01)

Dopaminergic agents: back to the basics – a small review
by: Neha Sharma, et al.
Published: (2017-12-01)

LCIG in treatment of non‐motor symptoms in advanced Parkinson’s disease: Review of literature
by: Walaa A. Kamel, et al.
Published: (2020-09-01)

Levodopa-Carbidopa Intestinal Gel Infusion Therapy Discontinuation: A Ten-Year Retrospective Analysis of 204 Treated Patients
by: Constantin VA, et al.
Published: (2020-07-01)

Levodopa-Carbidopa Intestinal Gel in Parkinson's Disease: A Systematic Review and Meta-Analysis
by: Libo Wang, et al.
Published: (2018-07-01)

Close relationships in Parkinson´s disease patients with device‐aided therapy
by: Monica Scharfenort, et al.
Published: (2021-06-01)

Improving levodopa delivery: IPX203, a novel extended-release carbidopa-levodopa formulation
by: Peter LeWitt, et al.
Published: (2023-01-01)

Comparative Effectiveness of Carbidopa/Levodopa Enteral Suspension and Deep Brain Stimulation on Pill Burden Reduction in Medicare Fee-for-Service Patients with Advanced Parkinson’s Disease
by: Michael J. Soileau, et al.
Published: (2023-01-01)

Clinical Use of On-Demand Therapies for Patients with Parkinson’s Disease and OFF Periods
by: Rajesh Pahwa, et al.
Published: (2023-05-01)